Trends in U.S. regulatory approvals of the biopharmaceutical therapeutic entities
Thesis (S.M.)--Harvard University--MIT Division of Health Sciences and Technology, 2005. === Includes bibliographical references (p. 89-92). === Pharmaceutical productivity, as measured by annual output of new molecular entities and new therapeutic biologics, has fallen significantly since reaching...
Main Author: | Graham, James B., 1976- |
---|---|
Other Authors: | Ernst R. Berndt and Issac S. Kohane. |
Format: | Others |
Language: | English |
Published: |
Massachusetts Institute of Technology
2006
|
Subjects: | |
Online Access: | http://hdl.handle.net/1721.1/30276 |
Similar Items
-
Understanding risk in a biopharmaceutical portfolio
by: Wagner, Alice Elizabeth, 1980-
Published: (2012) -
The accelerated approval process in oncology : an examination of the conversion rate of approved therapies to full approval
by: Kim, Jean Jinsun
Published: (2007) -
A comprehensive guide to the three biosimilar markets (Europe, US, Japan) and the regulatory pathways
by: Patrawala, Zeenat (Zeenat J.)
Published: (2011) -
Brokering strategic partnerships between Asian and western biopharmaceutical companies in the global biologics market : assessment of capabilities of Asian participants in the biologics contract manufacturing organization marketplace
by: Chun, Soo Jin, S.M. Massachusetts Institute of Technology
Published: (2011) -
Fulfilling the promise of targeted therapeutics in oncology via companion diagnostics : a perspective on pipeline trends and co-development strategies
by: Mehrotra, Anand
Published: (2012)